Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | +3.23% | -11.21% | +61.03% |
05-14 | Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says | MT |
05-13 | Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.03% | 28.86M | |
+9.78% | 115B | |
+11.73% | 106B | |
-2.59% | 21.96B | |
-13.00% | 21.87B | |
-5.29% | 19.21B | |
-3.95% | 18.08B | |
-38.57% | 17.71B | |
+6.84% | 14.32B | |
+34.61% | 12.42B |
- Stock Market
- Equities
- DRRX Stock
- News DURECT Corporation
- HC Wainwright Trims Price Target on Durect to $32 From $35, Maintains Buy Rating